Nothing Special   »   [go: up one dir, main page]

EP3512421A4 - Method and system for panel characterizations - Google Patents

Method and system for panel characterizations Download PDF

Info

Publication number
EP3512421A4
EP3512421A4 EP17851735.5A EP17851735A EP3512421A4 EP 3512421 A4 EP3512421 A4 EP 3512421A4 EP 17851735 A EP17851735 A EP 17851735A EP 3512421 A4 EP3512421 A4 EP 3512421A4
Authority
EP
European Patent Office
Prior art keywords
characterizations
panel
panel characterizations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17851735.5A
Other languages
German (de)
French (fr)
Other versions
EP3512421A1 (en
Inventor
Daniel Almonacid
Laurens KRAAL
Francisco OSSANDON
Juan Pablo CARDENAS
Jessica RICHMAN
Zachary APTE
Elisabeth BIK
Audrey Goddard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psomagen Inc
Original Assignee
Psomagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/606,743 external-priority patent/US10803991B2/en
Application filed by Psomagen Inc filed Critical Psomagen Inc
Publication of EP3512421A1 publication Critical patent/EP3512421A1/en
Publication of EP3512421A4 publication Critical patent/EP3512421A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Primary Health Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioethics (AREA)
EP17851735.5A 2016-09-16 2017-09-18 Method and system for panel characterizations Pending EP3512421A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395939P 2016-09-16 2016-09-16
US15/606,743 US10803991B2 (en) 2014-10-21 2017-05-26 Method and system for microbiome-derived diagnostics and therapeutics
US201762520058P 2017-06-15 2017-06-15
US201762525379P 2017-06-27 2017-06-27
PCT/US2017/052098 WO2018053443A1 (en) 2016-09-16 2017-09-18 Method and system for panel characterizations

Publications (2)

Publication Number Publication Date
EP3512421A1 EP3512421A1 (en) 2019-07-24
EP3512421A4 true EP3512421A4 (en) 2021-08-11

Family

ID=61619786

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17851735.5A Pending EP3512421A4 (en) 2016-09-16 2017-09-18 Method and system for panel characterizations

Country Status (11)

Country Link
EP (1) EP3512421A4 (en)
JP (1) JP7114091B2 (en)
KR (1) KR102486181B1 (en)
CN (1) CN109715059A (en)
AU (1) AU2017326564A1 (en)
BR (1) BR112019005025A8 (en)
CA (1) CA3036994A1 (en)
CO (1) CO2019003713A2 (en)
SG (1) SG11201901726QA (en)
WO (1) WO2018053443A1 (en)
ZA (1) ZA201901371B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109943636B (en) * 2019-04-11 2020-01-24 上海宝藤生物医药科技股份有限公司 Colorectal cancer microbial marker and application thereof
CN110669818B (en) * 2019-10-30 2021-08-24 中南大学 Multiple myeloma intestinal tract microbial marker, application and detection preparation
KR102373889B1 (en) * 2020-01-23 2022-03-15 주식회사 에이치이엠파마 Method and server for providing customized solution for improving gut environment
WO2022160358A1 (en) * 2021-02-01 2022-08-04 苏州大学附属儿童医院 Use of intestinal microorganism as marker of bronchopulmonary dysplasia in premature infant
KR102304402B1 (en) * 2021-03-26 2021-09-24 주식회사 에이치이엠파마 Method and diagnostic apparatus for determining obesity using machine learning model
WO2023053703A1 (en) 2021-09-29 2023-04-06 富士フイルム株式会社 Measurable and preferable feature selection method, program for selecting measurable and preferable feature, and measurable and preferable feature selection device
WO2023171482A1 (en) 2022-03-09 2023-09-14 富士フイルム株式会社 Method, device, and program
CN117838736B (en) * 2024-01-29 2024-06-14 吉林省农业科学院(中国农业科技东北创新中心) Application of bacillus coagulans JA845 in preparation of medicines for preventing and/or treating atherosclerosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112352A2 (en) * 2014-01-25 2015-07-30 uBiome, Inc. Method and system for microbiome analysis
WO2016065075A1 (en) * 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
WO2016168352A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112352A2 (en) * 2014-01-25 2015-07-30 uBiome, Inc. Method and system for microbiome analysis
WO2016065075A1 (en) * 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
WO2016168352A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALMONACID DANIEL E ET AL: "16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome", PLOS ONE, 3 May 2017 (2017-05-03), pages e0176555, XP055820597, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176555> [retrieved on 20210702], DOI: 10.1371/journal.pone.0176555 *
ALMONACID DANIEL E. ET AL: "16S rRNA gene sequencing as a clinical diagnostic aid for gastroitestinal related conditions", BIORXIV, 31 October 2016 (2016-10-31), XP055820608, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/084657v1.> [retrieved on 20210702], DOI: 10.1101/084657 *
CHIH-MIN CHIU ET AL: "Clinical detection of human probiotics and human pathogenic bacteria by using a novel high-throughput platform based on next generation sequencing", JOURNAL OF CLINICAL BIOINFORMATICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 13 January 2014 (2014-01-13), pages 1, XP021175161, ISSN: 2043-9113, DOI: 10.1186/2043-9113-4-1 *
NADJA B. KRISTENSEN ET AL: "Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials", GENOME MEDICINE, vol. 8, no. 1, 10 May 2016 (2016-05-10), XP055439213, DOI: 10.1186/s13073-016-0300-5 *
OTT STEPHAN J ET AL: "Quantification of intestinal bacterial populations by real-time PCR with a universal primer set and minor groove binder probes: a global approach to the enteric flora", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 42, no. 6, 1 June 2004 (2004-06-01), pages 2566 - 2572, XP002428203, ISSN: 0095-1137, DOI: 10.1128/JCM.42.6.2566-2572.2004 *
PORETSKY RACHEL ET AL: "Strengths and Limitations of 16S rRNA Gene Amplicon Sequencing in Revealing Temporal Microbial Community Dynamics", PLOS ONE, vol. 9, no. 4, 8 April 2014 (2014-04-08), pages e93827, XP055820823, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093827> DOI: 10.1371/journal.pone.0093827 *
See also references of WO2018053443A1 *
SIMEONI UMBERTO ET AL: "Gut microbiota analysis reveals a marked shift to bifidobacteria by a a starter infant formula containing a synbiotic of bovine milk-derived a oligosaccharides and Bifidobacterium animalis subsp lactisCNCM I-3446", ENVIRONMENTAL MICROBIOLOGY, vol. 18, no. 7, 2 December 2015 (2015-12-02), pages 2185 - 2195, XP055820498, Retrieved from the Internet <URL:https://sfamjournals.onlinelibrary.wiley.com/doi/epdf/10.1111/1462-2920.13108> [retrieved on 20210702], DOI: 10.1111/1462-2920.13144 *
THOMAS VINCENT ET AL: "Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies", FUTURE MICROBIOLOGY, FUTURE MEDICINE LTD, GB, vol. 10, no. 9, 1 January 2015 (2015-01-01), pages 1485 - 1504, XP009194769, ISSN: 1746-0913, DOI: 10.2217/FMB.15.87 *

Also Published As

Publication number Publication date
BR112019005025A8 (en) 2023-03-21
KR102486181B1 (en) 2023-01-06
BR112019005025A2 (en) 2019-06-18
KR20190055127A (en) 2019-05-22
CA3036994A1 (en) 2018-03-22
EP3512421A1 (en) 2019-07-24
WO2018053443A1 (en) 2018-03-22
ZA201901371B (en) 2019-11-27
JP7114091B2 (en) 2022-08-08
JP2019528729A (en) 2019-10-17
CN109715059A (en) 2019-05-03
AU2017326564A1 (en) 2019-03-28
CO2019003713A2 (en) 2019-04-30
SG11201901726QA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
EP3662686A4 (en) System and method for sidelink feedback
EP3519926A4 (en) Method and system for gesture-based interactions
EP3504032A4 (en) Systems and methods for assistive exosuit system
EP3549230A4 (en) Electric system and method for energizing the electric system
EP3495907A4 (en) Mount control method and system
EP3470880A4 (en) Ranging system and ranging method
EP3411548A4 (en) Systems and methods for entry control
EP3410239A4 (en) Vehicle control method and system
EP3261054A4 (en) Order pushing method and system
EP3400561A4 (en) System and method for multiple-round driver selection
EP3512421A4 (en) Method and system for panel characterizations
EP3451278A4 (en) Delivery-plan creating system and delivery-plan creating method
EP3457301A4 (en) Method and system for starting application
EP3471602A4 (en) Timeclock control system and method
EP3522039A4 (en) Position sharing method, apparatus and system
EP3510231A4 (en) System and method for plate alignment
EP3457666A4 (en) Method and system for starting application
EP3471066A4 (en) Anti-passback method, apparatus and system
EP3538372A4 (en) Direct-to-textile printing method and system
EP3508822A4 (en) Learning system and learning method for vehicle
EP3435351A4 (en) Vehicle control method, apparatus and system
EP3692009A4 (en) Biocementation method and system
EP3464673A4 (en) Shadow-mask-deposition system and method therefor
EP3590725A4 (en) Medium-issuing system and medium-issuing method
EP3318972A4 (en) System for providing application list and method therefor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
19U Interruption of proceedings before grant

Effective date: 20191011

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20201201

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PSOMAGEN, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61B0005050000

Ipc: G01N0033500000

A4 Supplementary search report drawn up and despatched

Effective date: 20210714

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20210708BHEP

Ipc: G16H 50/20 20180101ALI20210708BHEP

Ipc: G16B 40/10 20190101ALI20210708BHEP

Ipc: A61B 5/05 20210101ALI20210708BHEP

Ipc: A61B 1/00 20060101ALI20210708BHEP

Ipc: C12Q 1/04 20060101ALI20210708BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231128